Innovating Works

PHARMACOIDEA KFT.

Desconocido
PREDICTOM: PREDICTION OF ALZHEIMER S DISEASE USING AN AI DRIVEN SCREENING PLATFORM PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-03-single-stage Alzheimer’s disease (AD) and related disorders leading to dementia are associated with staggering costs and suffering. Recently, there has b...
2023-10-30 - 2027-10-31 | Financiado
ARDAT: Accelerating Research Development for Advanced Therapies PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage Major current hurdles for wide clinical use of AAV vectors are attributable primarily to: (i) host elimination by both immune and non-immune...
2020-11-11 - 2025-10-31 | Financiado
NEUROPA: Non invasive dynamic neural control by laser based technology PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT participó en un H2020: H2020-FETOPEN-2018-2020 Europe faces an enormous human toll of brain disorders, with an estimated 83 million people affected, and economic costs amounting to approx...
2019-09-24 - 2023-07-31 | Financiado
IM2PACT: Investigating Mechanisms and Models Predictive of Accessibility of Therapeutics IM2PACT Into The B... PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT participó en un H2020: H2020-JTI-IMI2-2017-12-two-stage The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery...
2018-12-14 - 2024-12-31 | Financiado
AETIONOMY: Aetionomy – Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of... PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT participó en un FP6: IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this ca...
2014-01-01 - 2018-12-31 | Financiado
COMPACT: Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT participó en un FP6: Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from...
2012-11-01 - 2017-10-31 | Financiado
COMPACT: Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT participó en un FP7: Most biopharmaceuticals (BP) currently on the market are recombinant proteins which are parenterally administered. These would benefit from...
Financiado
AETIONOMY: Aetionomy Organising Mechanistic Knowledge about Neurodegenerative Diseases for the Improvement of... PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT participó en un FP7: IMI’s Call 8 is geared to develop knowledge frameworks for ‘druggable mechanisms’ for two domains of pathophysiology. In response to this ca...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.